<!doctype html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
  <meta name="description" content="Eligibility">
  <meta name="author" content="AlcHepNet">
  <link rel="icon" href="../favicon.ico">
  <title>AlcHepNet - Observational Study Eligibility and Enrollment</title>
  <link href="../bootstrap.min.css" rel="stylesheet">
  <link href="../main.css" rel="stylesheet">
  <link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.4/css/all.min.css" rel="stylesheet">
  <script src="https://code.jquery.com/jquery-3.6.0.min.js"></script>
</head>

<body>
  <div id="navbar-include"></div>
  <div id="search-modal-include"></div>

  <main role="main">
    <div class="container marketing">
      <div class="container">
        <h3 class="section-title">AlcHepNet Observational Study Eligibility and Enrollment</h3>
        <div class="tr-indent2 lead">
          <table class="tr-layout_table mx-auto">
            <caption>Eligibility information</caption>
            <thead>
              <tr>
                <th id="elgType"></th>
                <th id="elgData"></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="elgType" style="text-align:right;white-space:nowrap;">Ages Eligible for Study: &nbsp; </td>
                <td headers="elgData" style="padding-left:1em">21 Years and older &nbsp; (Adult, Older Adult)</td>
              </tr>
              <tr>
                <td headers="elgType" style="text-align:right;white-space:nowrap;">Sexes Eligible for Study: &nbsp;
                </td>
                <td headers="elgData" style="padding-left:1em">All</td>
              </tr>
              <tr>
                <td headers="elgType" style="text-align:right;white-space:nowrap;">Accepts Healthy Volunteers: &nbsp;
                </td>
                <td headers="elgData" style="padding-left:1em">Yes</td>
              </tr>
              <tr>
                <td headers="elgType" style="text-align:right;white-space:nowrap;">Sampling Method: &nbsp; </td>
                <td headers="elgData" style="padding-left:1em">Probability Sample</td>
              </tr>
            </tbody>
          </table>

          <div class="ct-header3" style="margin-top:2ex">
            <h3>Study Population</h3>
          </div>
          <div class="tr-indent2">Any subject with Alcohol-associated hepatitis, Heavy healthy drinkers, and Healthy
            controls</div>

          <div class="ct-header3" style="margin-top:2ex">
            <h4>Criteria</h4>
          </div>
          <div class="tr-indent2">
            <p style="margin-top:1ex; margin-bottom:1ex;"><b>CASES:</b> Heavy drinkers with alcohol-associated hepatitis
            </p>
            <p style="margin-top:1ex; margin-bottom:1ex;"> Inclusion criteria</p>
            <ol style="margin-top:1ex; margin-bottom:1ex;">
              <li style="margin-top:0.7ex;">A clinical diagnosis of alcohol-associated hepatitis</li>
              <li style="margin-top:0.7ex;">Serum total bilirubin &gt;3 mg/dL</li>
              <li style="margin-top:0.7ex;">Subject or guardian ability to understand and willingness to provide written
                consent</li>
              <li style="margin-top:0.7ex;">Age greater or equal to 21 years</li>
              <li style="margin-top:0.7ex;">Re-enrolment of an alcohol-associated hepatitis donor is permissible up to 4
                times if the donor presents with a new episode of alcohol-associated hepatitis 24 weeks or longer after
                the most recent enrolment in the study</li>
            </ol>
            <p style="margin-top:1ex; margin-bottom:1ex;">Exclusion criteria</p>
            <ol style="margin-top:1ex; margin-bottom:1ex;">
              <li style="margin-top:0.7ex;">Liver disease significantly caused by hemochromatosis, autoimmune liver
                disease, Wilson disease, NAFLD, and acute viral hepatitis</li>
              <li style="margin-top:0.7ex;">(NOTE: The presence of chronic hepatitis C, hepatitis B, or HIV is not
                exclusion to participation.) Pregnant or breast feeding Based on the judgment of the investigator,
                subject is not capable of understanding or complying with the study requirements.</li>
            </ol>
            <p style="margin-top:0ex; margin-bottom:1ex;"><b>CONTROLS:</b> Heavy drinkers without significant liver
              disease </p>
            <p>Inclusion criteria</p>
            <ol style="margin-top:0ex; margin-bottom:1ex;">
              <li>History of chronic alcohol consumption sufficient to cause liver damage. Generally, this is considered
                to be &gt;40 g/day or &gt;280g/week on average for women and &gt;60 g/day or &gt;420 g/week on average
                for men, for many years (usually decades). Judgement about chronic alcohol consumption will be made by
                the site investigator.
              </li>
              <li> Subject or guardian ability to understand and willingness to provide written consent
              </li>
              <li> Age greater or equal to 21 years </li>
            </ol>
            <p>Exclusion criteria</p>
            <ol style="margin-top:1ex; margin-bottom:1ex;">
              <li style="margin-top:0.7ex;">Past evidence of alcoholic liver disease, defined as a bilirubin &gt; 2.0
                mg/dL, an AST &gt; 1.5 ULN, and any hospital admission for liver disease, or the presence of esophageal
                varices or ascites (at any time in the past).</li>
              <li style="margin-top:0.7ex;">Liver disease significantly caused by hemochromatosis, autoimmune liver
                disease, Wilson disease, NAFLD, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C,
                hepatitis B, or HIV is not exclusion to participation.)</li>
              <li style="margin-top:0.7ex;">Alcohol intake at less than 40 g/day or 280g/week on average for women and
                60 g/day or 420 g/week on average for men for longer than the past 28 days</li>
              <li style="margin-top:0.7ex;">If liver stiffness has been assessed within the prior 90 days, then
                stiffness suggesting fibrosis of F1 or greater is excluded. For Fibroscan, this is a fibrosis score
                &gt;7.0 kPa.</li>
              <li style="margin-top:0.7ex;">Pregnant or breast feeding</li>
              <li style="margin-top:0.7ex;">
                <p style="margin-top:0ex; margin-bottom:1ex;">Any of the following laboratory abnormalities within 90
                  days prior to signing the consent.</p>
                <ol style="margin-top:1ex; margin-bottom:1ex;">
                  <li style="margin-top:0.7ex;">Total bilirubin: &gt;ULN*</li>
                  <li style="margin-top:0.7ex;">
                    <p style="margin-top:0ex; margin-bottom:1ex;">INR: &gt; 1.4 5</p>
                    <p style="margin-top:0ex; margin-bottom:1ex;">*Individuals with a diagnosis of Gilbert's can have
                      total bilirubin up to 3.0 mg/dL and still be eligible for participation.</p>
                  </li>
                </ol>
              </li>
            </ol>
            <p style="margin-top:0ex; margin-bottom:1ex;">
            <h3>Healthy Controls</h3>
            </p>
            <p style="margin-top:0ex; margin-bottom:1ex;">Inclusion criteria</p>
            <ol style="margin-top:0ex; margin-bottom:1ex;">
              <li> AUDIT-C scores of &lt;4 for men and &lt;3 for women (signifying no alcohol misuse) </li>
              <li> Abstinent (consumption of less than one standard drink/week) during the 6 months prior to enrolment
              </li>
              <li> Ability to understand and willingness to provide written consent.</li>
            </ol>
            <p> Exclusion criteria</p>
            <ol style="margin-top:1ex; margin-bottom:1ex;">
              <li style="margin-top:0.7ex;">Clinical history or laboratory evidence of liver disease including alcoholic
                liver disease, NAFLD, hemochromatosis, alcohol-associated hepatitis, autoimmune liver disease, Wilson
                disease, hepatitis C, or hepatitis B.</li>
              <li style="margin-top:0.7ex;">Presence of diabetes (requiring treatment with oral agents or insulin).</li>
              <li style="margin-top:0.7ex;">Significant heart disease (prior history of heart disease, other than
                hypertension)</li>
              <li style="margin-top:0.7ex;">Chronic lung disease (requiring chronic treatment)</li>
              <li style="margin-top:0.7ex;">Immune related conditions (such as Crohn's disease, rheumatoid arthritis,
                ulcerative colitis, systemic lupus erythematosus, severe psoriasis, etc.)</li>
              <li style="margin-top:0.7ex;">Known infection with HIV</li>
              <li style="margin-top:0.7ex;">Presumed infection, or use of antibiotics or other medications (e.g.,
                corticosteroids) that would affect immune function, within the past 14 days</li>
              <li style="margin-top:0.7ex;">BMI&gt;35</li>
              <li style="margin-top:0.7ex;">Current or known history of cancer (except in situ carcinoma of the cervix
                or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment
              </li>
              <li style="margin-top:0.7ex;">Pregnant or breast feeding</li>
              <li style="margin-top:0.7ex;">
                <p style="margin-top:0ex; margin-bottom:1ex;">Any of the following laboratory abnormalities within 90
                  days prior to signing the consent.</p>
                <ol style="margin-top:1ex; margin-bottom:1ex;">
                  <li style="margin-top:0.7ex;">Hemoglobin: &lt;10 g/dL</li>
                  <li style="margin-top:0.7ex;">Conjugated bilirubin: &gt; ULN</li>
                  <li style="margin-top:0.7ex;">INR: &gt; 1.4</li>
                  <li style="margin-top:0.7ex;">AST: &gt;40 IU/mL</li>
                  <li style="margin-top:0.7ex;">ALT: &gt;40 IU/mL</li>
                </ol>
              </li>
              <li style="margin-top:0.7ex;">Based on the judgment of the investigator, subject is not capable of
                complying with the study requirements</li>
            </ol>
          </div>


          <!-- <hr class="featurette-divider"> -->

          <div class="row featurette trial-basis" style="display:none">
            <div class="col">
              <h1>AlcHepNet Clinical Trial Eligibility and Enrollment</h1>
            </div>
          </div>
          <div class="row featurette trial-basis" style="display:none">
            <div class="col">

              Inclusion Criteria
              <ol style="margin-top:1ex; margin-bottom:1ex;">
                <li style="margin-top:0.7ex;">AH, as defined by the NIAAA pan-consortia for AH:</li>
                <ol style="margin-top:1ex; margin-bottom:1ex;" type="a">
                  <li style="margin-top:0.7ex;">Onset of jaundice (defined as serum total bilirubin >3 mg/dL) within the
                    prior 8 weeks to
                    screening visit</li>
                  <li style="margin-top:0.7ex;">Regular consumption of alcohol with an intake of > 40 gm daily or >280gm
                    weekly
                    on average for women and > 60 gm daily or >420gm weekly on average for men
                    for 6 months or more, with less than 8 weeks of abstinence before onset of jaundice</li>
                  <li style="margin-top:0.7ex;">AST > 50 IU/l</li>
                  <li style="margin-top:0.7ex;">AST:ALT > 1.5 and both values &lt; 400 IU/l</li>
                  <li style="margin-top:0.7ex;">and/or histological evidence of AH*</li>
                  <p>* In patients with possible AH or AH with confounding factors such as possible ischemic
                    hepatitis, possible DILI, uncertain history of alcohol use (e.g., patient denies excessive alcohol
                    use), and atypical/abnormal laboratory tests (e.g., AST &lt; 50 IU/mL or > 400 IU/mL,
                    AST/ALT ratio &lt; 1.5), antinuclear antibody > 1:160 or SMA > 1:80, a liver biopsy will be
                    performed to confirm AH and exclude competing etiologies</p>
                </ol>
                <li style="margin-top:0.7ex;">MELD 20-35 on day of randomization.
                </li>
              </ol>
              Exclusion Criteria
              <ol style="margin-top:1ex; margin-bottom:1ex;">
                <li style="margin-top:0.7ex;">MELD SCORE <20 or> 35</li>
                <li style="margin-top:0.7ex;">Active sepsis (positive blood or ascitic cultures) with Systemic
                  Inflammatory Response
                  Syndrome (SIRS) or hemodynamic compromise requiring intravenous pressors to
                  maintain tissue perfusion</li>
                <li style="margin-top:0.7ex;">Pneumonia as evidenced by radiological exam</li>
                <li style="margin-top:0.7ex;">Multi-organ failure</li>
                <li style="margin-top:0.7ex;">Renal failure defined by GFR &lt;50 mL/min.</li>
                <li style="margin-top:0.7ex;">Clinically active C. diff infection</li>
                <li style="margin-top:0.7ex;">History of imaging of the liver (ultrasound, computerized tomography or
                  magnetic
                  resonance) showing other causes of jaundice</li>
                <li style="margin-top:0.7ex;">History of other liver diseases including hepatitis B (positive HBsAg or
                  HBV DNA),
                  hepatitis C (positive HCV RNA), autoimmune hepatitis, Wilson disease, genetic
                  \hemochromatosis, alpha1-antitrypsin deficiency or strong suspicion of Drug Induced
                  Liver Injury (DILI)</li>
                <li style="margin-top:0.7ex;">History of HIV infection (positive HIV RNA or on treatment for HIV
                  infection)</li>
                <li style="margin-top:0.7ex;">History or presence of cancer (including hepatocellular carcinoma) other
                  than nonmelanoma
                  skin cancer</li>
                <li style="margin-top:0.7ex;">History of other significant medical problems such as autoimmune diseases,
                  severe
                  asthma, psoriasis, Inflammatory Bowel Disease (IBD), etc. that might require
                  immunosuppressive treatments</li>
                <li style="margin-top:0.7ex;">Pregnancy or breastfeeding</li>
                <li style="margin-top:0.7ex;">Prior exposure to experimental therapies in last 3 months</li>
                <li style="margin-top:0.7ex;">Prior exposure to systemic corticosteroid (glucocorticoid) or
                  immunosuppressive therapy
                  for more than 4 days within previous 30 days</li>
                <li style="margin-top:0.7ex;">Need for inotropic pressor support to maintain perfusion to critical
                  organs within prior
                  48 hours before randomization and initiation of experimental treatment</li>
                <li style="margin-top:0.7ex;">Clinically significant pancreatitis- abdominal pain, elevated lipase (> 3
                  X ULN) and at least
                  edema of pancreas with fat-stranding on CT scan</li>
                <li style="margin-top:0.7ex;">Total WBC count > 30000/mm3</li>
                <li style="margin-top:0.7ex;">Known allergy or intolerance to therapeutic agents to be tested</li>
                <li style="margin-top:0.7ex;">Inability to voluntarily obtain informed consent from participant or
                  guardian</li>
                <li style="margin-top:0.7ex;">Perceived inability to follow study procedures and comply with protocol
                </li>
                <li style="margin-top:0.7ex;">Platelet count &lt; 50,000.</li>
              </ol>
              The participants for this study will be recruited from a hospitalized population of participants
              meeting the eligibility criteria outlined above who live within one day travel from one of the
              participating clinical centers and who have provided informed consent to participate in this
              clinical trial and who are willing to continue their participation for the anticipated follow-up
              period of the trial. Although the primary endpoint is survival at 90 days, follow-up visits will be
              continued up to 6 months.

            </div>
          </div>

          <!-- <hr class="featurette-divider"> -->
          <!-- <div class="row featurette">
          <div class="col">
          <h2 class="featurette-heading">AlcHepNet Organizations</h2>
            <img class="org-logo img-fluid mx-auto" src="sites_20250610.png" alt="Participating organization logos"/>
          </div>
        </div> -->

          <!-- <hr class="featurette-divider"> -->

          <!-- <div class="row featurette">
        <div class="col text-center">
			<p class="lead">AlcHepNet is a clinical and translational research initiative funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of NIH.</p>
         </div>
        </div> -->
          <!-- /END THE FEATURETTES -->
          <!-- <hr class="featurette-divider"> -->
        </div><!-- /.container -->

      </div>
    </div>
  </main>

  <div id="footer-include"></div>

  <script src="../popper.min.js"></script>
  <script src="../bootstrap.min.js"></script>
  <script src="../simple-dropdown.js"></script>
  <script>
    $(function () {
      $("#navbar-include").load("../navbar.html", function () {
        $("#navbar-include a").each(function() {
          var href = $(this).attr("href");
          if (href && !href.startsWith("http") && !href.startsWith("#")) {
            $(this).attr("href", "../" + href);
          }
        });
        
        $("#navbar-include img").each(function() {
          var src = $(this).attr("src");
          if (src && !src.startsWith("http") && !src.startsWith("data:") && !src.startsWith("/")) {
            $(this).attr("src", "../" + src);
          }
        });
        console.log('Navbar loaded and links updated');
      });
      $("#search-modal-include").load("../search-modal.html");
      $("#footer-include").load("../footer.html", function () {
        console.log('Footer loaded');
      });
    });
  </script>
</body>

</html>